Clinical trial
Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm
NCT01913600 is registered in ClinicalTrials.gov with Medtronic Vascular as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm
- Lead sponsor
- Medtronic Vascular
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- July 31, 2013
- Completion date
- December 31, 2018
- Enrollment
- 56 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.